Aniline Compounds

• 

  Subject Areas on Research

  • 1,2-Difunctionalization of Aryl Triflates: A Direct and Modular Access to Diversely Functionalized Anilines. 
  • 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. 
  • A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 
  • A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure. 
  • A gas nanosensor unaffected by humidity. 
  • A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. 
  • A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. 
  • A small molecule inhibitor of alpha4 integrin-dependent cell migration. 
  • A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. 
  • A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. 
  • Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 
  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 
  • An approach for fabricating self-assembled monolayer of Ag nanoparticles on gold as the SERS-active substrate. 
  • Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 
  • Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults. 
  • Cerebral Amyloid and Cognition after Surgery: Reply. 
  • Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. 
  • Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 
  • Consequences of chemical modifications on the free radical reactions of human hemoglobin. 
  • Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. 
  • Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. 
  • Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. 
  • Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). 
  • Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. 
  • Effectiveness of Florbetapir PET Imaging in Changing Patient Management. 
  • Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat. 
  • Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat. 
  • Electrical and gas sensing properties of polyaniline functionalized single-walled carbon nanotubes. 
  • Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. 
  • Expanding the synthetic method and structural diversity potential for the intramolecular Aza Diels-Alder cyclization. 
  • Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition. 
  • Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. 
  • Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 
  • Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. 
  • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 
  • Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. 
  • Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. 
  • Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 
  • Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. 
  • Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA. 
  • Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. 
  • Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. 
  • Irreversible stimulation of adenylate cyclase activity of fat cell membranes of phosphoramidate and phosphonate analogs of GTP. 
  • Isolation from the mushroom Agaricus bisporus and chemical synthesis of gamma-L-glutaminyl-4-hydroxybenzene. 
  • Kinetics and Mechanism of the Gold-Catalyzed Hydroamination of 1,1-Dimethylallene with N-Methylaniline. 
  • Leflunomide for polyomavirus type BK nephropathy. 
  • Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. 
  • Metabolic network failures in Alzheimer's disease: A biochemical road map. 
  • Microdroplet dissolution into a second-phase solvent using a micropipet technique: test of the Epstein-Plesset model for an aniline-water system. 
  • Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. 
  • Modulating unimolecular charge transfer by exciting bridge vibrations. 
  • Molecular memory by reversible translocation of calcium/calmodulin-dependent protein kinase II. 
  • Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. 
  • Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. 
  • Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. 
  • Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. 
  • Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats. 
  • Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors. 
  • Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. 
  • Retinal microvasculature changes in amyloid-negative subcortical vascular cognitive impairment compared to amyloid-positive Alzheimer's disease. 
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. 
  • Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. 
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. 
  • Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. 
  • Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 
  • Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. 
  • Use of florbetapir-PET for imaging beta-amyloid pathology. 
  • Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
• 

  Keywords of People

  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology